Cargando…

344. HIV and Diabetes in the Era of Antiretroviral Therapy

BACKGROUND: With advancements in ART, non-AIDS comorbidities are becoming more common among people living with HIV (PWH). In this analysis, we identified PWH followed at a single Ryan White HIV Clinic in Alabama and determined the overall prevalence of diabetes (DM). We then evaluated the cohort for...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabbaj. Spieler, Gabriel, Overton, Edgar T, Willig, Amanda, Burkholder, Greer A, Varshney, Mohit, Westfall, Andrew O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810259/
http://dx.doi.org/10.1093/ofid/ofz360.417
_version_ 1783462206623449088
author Sabbaj. Spieler, Gabriel
Overton, Edgar T
Willig, Amanda
Burkholder, Greer A
Varshney, Mohit
Westfall, Andrew O
author_facet Sabbaj. Spieler, Gabriel
Overton, Edgar T
Willig, Amanda
Burkholder, Greer A
Varshney, Mohit
Westfall, Andrew O
author_sort Sabbaj. Spieler, Gabriel
collection PubMed
description BACKGROUND: With advancements in ART, non-AIDS comorbidities are becoming more common among people living with HIV (PWH). In this analysis, we identified PWH followed at a single Ryan White HIV Clinic in Alabama and determined the overall prevalence of diabetes (DM). We then evaluated the cohort for risk factors associated with DM. METHODS: The records of all PWH who attended at least one routine care HIV primary provider visit from 2009 to 2018 at the UAB 1917 HIV Clinic in Birmingham, AL were abstracted. We defined DM as individuals having ≥1 of the following: (1) diagnosis of DM and receiving any diabetic medication, (2) Hgb A1c ≥ 6.5%, (3) any glucose >200 mg/dL. We evaluated the association of traditional, demographic, and HIV-specific risk factors with PWH with and without DM using Chi-square and Wilcoxon rank-sum testing. Univariate significance and amount of missing data were considered when constructing the multivariable logistic regression model to identify independent associations. RESULTS: Of the 5247 PWH assessed, 1178 were female (23%), 45 transgender persons (1%); 3235 (62%) black, 1834 (35%) white. At baseline, the median age was 37.5 years, median BMI 24.5 kg/m(2), median CD4+ count 333 c/mm(3). Overall, 1110 PWH developed DM (21%). By univariate analysis, numerous traditional, demographic and HIV-related risk factors were associated with diagnosis of DM (see Table 1). By multivariable analysis, the following factors were independently associated with DM: traditional (antihypertensive use, aspirin use, glucocorticoid use, statin use, comorbid CKD, comorbid liver disease), demographic (black race, female gender, older age), and HIV-related (nadir CD4) (P < 0.05 for all). CONCLUSION: Over 20% of PWH had a diagnosis of DM. Both traditional and HIV-related factors were independently associated with DM. Notably, lower nadir CD4 and longer time to ART initiation were key HIV-related factors. Additionally, a majority of PWH with DM had multimorbidity (85%) and polypharmacy (90%). Despite the lower complexity of modern ART, the care of PWH remains challenging, partly because of cardiometabolic comorbidities, including DM. Effective diabetes prevention and treatment strategies for PWH should be prioritized. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810259
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68102592019-10-28 344. HIV and Diabetes in the Era of Antiretroviral Therapy Sabbaj. Spieler, Gabriel Overton, Edgar T Willig, Amanda Burkholder, Greer A Varshney, Mohit Westfall, Andrew O Open Forum Infect Dis Abstracts BACKGROUND: With advancements in ART, non-AIDS comorbidities are becoming more common among people living with HIV (PWH). In this analysis, we identified PWH followed at a single Ryan White HIV Clinic in Alabama and determined the overall prevalence of diabetes (DM). We then evaluated the cohort for risk factors associated with DM. METHODS: The records of all PWH who attended at least one routine care HIV primary provider visit from 2009 to 2018 at the UAB 1917 HIV Clinic in Birmingham, AL were abstracted. We defined DM as individuals having ≥1 of the following: (1) diagnosis of DM and receiving any diabetic medication, (2) Hgb A1c ≥ 6.5%, (3) any glucose >200 mg/dL. We evaluated the association of traditional, demographic, and HIV-specific risk factors with PWH with and without DM using Chi-square and Wilcoxon rank-sum testing. Univariate significance and amount of missing data were considered when constructing the multivariable logistic regression model to identify independent associations. RESULTS: Of the 5247 PWH assessed, 1178 were female (23%), 45 transgender persons (1%); 3235 (62%) black, 1834 (35%) white. At baseline, the median age was 37.5 years, median BMI 24.5 kg/m(2), median CD4+ count 333 c/mm(3). Overall, 1110 PWH developed DM (21%). By univariate analysis, numerous traditional, demographic and HIV-related risk factors were associated with diagnosis of DM (see Table 1). By multivariable analysis, the following factors were independently associated with DM: traditional (antihypertensive use, aspirin use, glucocorticoid use, statin use, comorbid CKD, comorbid liver disease), demographic (black race, female gender, older age), and HIV-related (nadir CD4) (P < 0.05 for all). CONCLUSION: Over 20% of PWH had a diagnosis of DM. Both traditional and HIV-related factors were independently associated with DM. Notably, lower nadir CD4 and longer time to ART initiation were key HIV-related factors. Additionally, a majority of PWH with DM had multimorbidity (85%) and polypharmacy (90%). Despite the lower complexity of modern ART, the care of PWH remains challenging, partly because of cardiometabolic comorbidities, including DM. Effective diabetes prevention and treatment strategies for PWH should be prioritized. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810259/ http://dx.doi.org/10.1093/ofid/ofz360.417 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Sabbaj. Spieler, Gabriel
Overton, Edgar T
Willig, Amanda
Burkholder, Greer A
Varshney, Mohit
Westfall, Andrew O
344. HIV and Diabetes in the Era of Antiretroviral Therapy
title 344. HIV and Diabetes in the Era of Antiretroviral Therapy
title_full 344. HIV and Diabetes in the Era of Antiretroviral Therapy
title_fullStr 344. HIV and Diabetes in the Era of Antiretroviral Therapy
title_full_unstemmed 344. HIV and Diabetes in the Era of Antiretroviral Therapy
title_short 344. HIV and Diabetes in the Era of Antiretroviral Therapy
title_sort 344. hiv and diabetes in the era of antiretroviral therapy
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810259/
http://dx.doi.org/10.1093/ofid/ofz360.417
work_keys_str_mv AT sabbajspielergabriel 344hivanddiabetesintheeraofantiretroviraltherapy
AT overtonedgart 344hivanddiabetesintheeraofantiretroviraltherapy
AT willigamanda 344hivanddiabetesintheeraofantiretroviraltherapy
AT burkholdergreera 344hivanddiabetesintheeraofantiretroviraltherapy
AT varshneymohit 344hivanddiabetesintheeraofantiretroviraltherapy
AT westfallandrewo 344hivanddiabetesintheeraofantiretroviraltherapy